Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group
of small vessel vasculitides characterized by granulomatous and neutrophilic tissue …

There continues to be rapid advancement in our understanding of the pathogenesis of
immune-mediated kidney disease. This progress has culminated in the development of …

Background The C5a receptor inhibitor avacopan is being studied for the treatment of
antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Methods In this …

Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis.
However, glucocorticoids used as treatment contribute to the morbidity and mortality of …

Abstract The 1996 Five-Factor Score (FFS) for systemic necrotizing vasculitides (polyarteritis
nodosa [PAN], microscopic polyangiitis [MPA], and Churg-Strauss syndrome [CSS]) is used …

Background Current guidelines advise that rituximab or cyclophosphamide should be used
for the treatment of organ-threatening disease in anti-neutrophil cytoplasm antibody (ANCA) …

The updated nomenclature for vasculitis defines this varied group of disorders by aetiology,
specific features of pathogenesis and clinical symptoms; diagnostic and classification criteria …

The aim of this study was to describe the clinical characteristics of ANCA-associated
vasculitides (AAV) at presentation, in a wide cohort of Spanish patients, and to analyze the …

Introduction Evidence from a number of open-label, uncontrolled studies has suggested that
rituximab may benefit patients with autoimmune diseases who are refractory to standard-of …

Background: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a serious,
often life-threatening disease. In new-onset disease or a relapse, the standard treatment is …